Our previous studies have shown the therapeutic efficacy and the underlying mechanisms of Peony-Glycyrrhiza Decoction (PGD), an herbal preparation, in treating antipsychotic-induced hyperprolactinemia in cultured cells, animal models and human subjects. In the present study, we further evaluated pharmacokinetic interactions of PGD with clozapine (CLZ) in human liver microsomes (HLM), recombinantly expressed cytochrome P450s (CYPs), and flavin-containing monooxygenases (FMOs).
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Introduction
Although antipsychotic agents are the mainstay in treating schizophrenia, their clinical use is largely limited due to undesirable side effects that often result in discontinuation and relapse (Kane and Correll, 2010) . This has led to a demand for the development of alternative strategies to improve medication compliance and antipsychotic response.
Herbal medicines may possess the potential to reduce adverse side effects associated with antipsychotic treatment (Zhang et al., 2010) . It has been reported that Peony-Glycyrrhiza Decoction (PGD), a traditional Chinese herbal formula consisting of Paeonia (peony) and Glycyrrhiza (liquorice) radices, can alleviate antipsychotic-induced hyperprolactinemia (hyperPRL) (Costa et al., 2006; Xu, 2003; Yamada et al., 1996 Yamada et al., , 1997 Yamada et al., , 1999 Yuan, 2008) . In our controlled trial, additional PGD both lowered antipsychotic-induced hyperPRL and improved the related symptoms in women with schizophrenia (Yuan et al., 2008) . Studies using cultured cells and animal models have further revealed that the anti-hyperPRL effects of PGD are associated with the modulation of dopamine D 2 receptor and transporters and normalization of sex hormone dysfunction (Wang et al., 2012a) . Major bioactive compounds of PGD can modulate multiple anti-apoptotic and pro-apoptotic pathways at subcellular and molecular levels in targeted cells (Wang et al., 2013a,b; 2014a,b) . However, it is unclear whether herb-drug kinetic interactions are involved in the therapeutic effects of PGD.
With an increasing use of herbal medicine in managing psychiatric disease, herb-drug interactions have become an important issue in clinical practice (Zhang et al., 2010 (Zhang et al., , 2011 . This is particularly apparent in China where herbal medicine has become an important therapeutic approach to psychiatric disorders (Zhang et al., 2010) . Our recent epidemiological study has found that approximately 37% of schizophrenic patients sought herbal medicine treatment while they were under antipsychotic medication (Zhang et al., 2011) . However, supplementary use of herbal medicine can result in both beneficial and adverse clinical outcomes (Peterson et al., 2008; Przekop and Lee, 2009; DMD # 62653 5 of 27 Zhang et al., 2011) . Therefore, identifying potential interactions between herbal and antipsychotic agents is critical for promoting drug safety in clinical psychiatry.
Clozapine (CLZ) is the most commonly prescribed antipsychotic drug for long-term maintenance treatment of schizophrenia in China (Tang et al., 2008) . Our epidemiological study has shown that CLZ is often concomitantly used with herbal medicine, which may result in adverse clinical outcomes (Zhang et al., 2011) .
Clozapine is metabolized to N-demethylated CLZ (norCLZ) and N-oxygenated CLZ (CLZ-N-oxide) via hepatic cytochrome P450 (CYP) enzymes, mainly CYP1A2, CYP3A4, CYP2D6, CYP2C9, and CYP2C19 (Chetty and Murray, 2007) . CYPs also play a critical role in the kinetic interaction between liquorice and peony and conventional drugs (Chen et al., 2002; Wang et al., 2013c; Wu et al., 2012; Zhou et al., 2003) . Flavin-containing monooxygenases (FMOs) are hepatic microsomal enzymes with importance in catalyzing massive xenobiotics (Krueger et al., 2005) . FMOs and CYPs share many similarities in tissue distribution, subcellular location and substrate specificity (Krueger et al., 2005) . FMOs, in particular FMO3, may be also involved in the N-oxygenation of CLZ (Tugnait et al., 1997; Fang et al., 1998; Fang, 2000; Zhang et al., 2008) .
We hypothesize that PGD may affect CLZ metabolism by mediating related CYP and FMO activities in liver microsomes. To test this hypothesis, we evaluated the kinetic effects of PGD, individual peony and liquorice preparations, two individual preparations in combination and the major bioactive constituents of PGD on CLZ metabolism in human liver microsomes (HLM), recombinantly expressed CYP, and Herbal preparation and determination of quality. Four herbal preparations used in the present study (PGD, individual Paeonia and Glycyrrhiza preparations, and the combination of the two individual herbal preparations) came from the same batches previously reported (Wang et al., 2012a) . The raw materials of Paeonia and Glycyrrhiza radices were supplied by the Pharmacy of School of Chinese Medicine at the University of Hong Kong (HKU). For PGD preparation, water extraction was utilized to optimally preserve its bioactive constituents, as recommended by the Chinese Pharmacopoeia (Chinese Pharmacopoeia Commission, 2010) . The extraction was conducted in an automatic boiling machine. Sliced and broiled Paeonia and Glycyrrhiza radices (50 g each) were mixed, immersed, and boiled in a 10-fold volume of distilled water for 2 hours. This process was repeated twice as previously reported (Yuan et al., 2008) . The extracted solution was pooled, concentrated, and freeze-dried to yield powder at a 1:5 ratio with raw materials in weight. Individual Paeonia radix (peony) (PR) and Glycyrrhiza radix (liquorice) (GR) were also prepared as done for PGD. The resulting powder was dissolved in water at a concentration of 250 mg/ml to create a stock solution for further use. To ensure the quality of the herbal preparation, three batches of PGD used in this study were prepared; inter-batch coefficients of variation (CV) of the contents of the five known constituents (mean ± SEM, mg/g), paeoniflorin (17.76 ± 0.39), liquiritin (1.05 ± 0.11), liquiritigenin (2.07 ± 0.30), glycyrrhizic acid (0.48 ± 0.04), and glycyrrhetinic acid (1.16 ± 0.08), were measured using reverse-phase high-performance liquid chromatography (HPLC). CVs of all constituents measured were <15% across the three batches as reported previously (Wang et al., 2012a) . concentrations used for the five constituents were 3-to 10-fold higher than those used in in vitro pharmacological and therapeutic experiments (Wang et al., 2012a; 2013a,b; 2014a,b) . The enzymatic reactions were conducted in polypropylene tubes in triplicate at 37°C in a water bath. CLZ, inhibitor, and HLM (50 μ g) were mixed and pre-incubated in potassium phosphate buffer (0.1 M, pH 7.4) for 10 min, initiated by adding the coenzyme NADPH (1 mM), and terminated 15 min later by adding an equivalent volume of ice-cold acetonitrile. The samples were centrifuged at 12,000 × g two-sided P value less than 0.05.
Results
The effects of PGD and its major constituents on CLZ metabolism in HLM. K m values of 92.6 µM for norCLZ and 43.9 µM for CLZ N-oxide were obtained from pilot experiments. We then used 100 µM CLZ in dose-response experiment of PGD. In the presence of 100 µM CLZ, IC 50 of PGD in inhibiting the production of CLZ-N-oxide and norCLZ was 2.41 mg/ml and 2.00 mg/ml, respectively (Fig. 1) . We then used 2.5 mg/ml PGD as the reference concentration for further experiments as this concentration is surrounding IC 50 and has been widely used in our previous studies (Wang et al., 2012a; 2013a,b; 2014a,b) . Kinetic variables of the four herbal preparations in inhibiting CLZ metabolism are summarized in Table 1 Table 2 ). The other four constituents had no effect on either norCLZ or CLZ-N-oxide (data not shown).
This article has not been copyedited and formatted. The final version may differ from this version. showed an IC 50 of 44.3 mg/ml of PGD in inhibiting the production of CLZ-N-oxide (Fig. 4) . The decrease in the production of CLZ-N-oxide in the presence of 2.5 and 5 mg/ml of PGD was not significantly different from that in the absence of PGD (96.8%
and 88.3%, respectively). Even at 10 and 25 mg/ml of PGD, 74.9% and 59.0% CLZ-N-oxide was still produced, respectively (Fig. 4) .
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
The present study represents an attempt to characterize metabolism-based interactions between herbal and antipsychotic agents. PGD often serves as adjunctive therapy to treat antipsychotic-induced hyperPRL (Zhang et al., 2010) . Our previous studies have demonstrated the anti-hyperPRL effects of PGD in cultured cells, animal models and patients with schizophrenia and the underlying mechanisms (Wang et al., 2012a; 2013a,b; 2014a,b; Yuan et al., 2008) . In the present study, a series of in vitro experiments were employed to further evaluate the kinetic properties of PGD, the individual herbal preparations, and its major constituents on CLZ metabolism.
Clozapine (CLZ) is metabolized to norCLZ and CLZ-N-oxide mainly via hepatic cytochrome P450 (CYP) enzymes (Chetty and Murray, 2007) . The present study first examined the kinetic effects of PGD in HLM. We found that PGD at 2.5 mg/ml, an effective dose inducing pharmacological and therapeutic response, exerted significant effects in reducing V max and C int and increasing K m values of the two CLZ metabolites, norCLZ and CLZ-N-oxide, indicating that this herbal preparation possesses the capacity to suppress CLZ metabolism in vitro. Of the CYP enzyme systems, CYP1A2
and CYP3A4 play a major role in the metabolism of CLZ, with a minor contribution from other CYP isoforms (Chetty and Murray, 2007) . We therefore further examined the effects of PGD on individual CYP activity using recombinantly expressed CYPs.
The current study showed that PGD had a moderate inhibitory potency toward CYP1A2, CYP2C19, and CYP3A4 and a weak potency toward CYP2D6 in the demethylation of CLZ. PGD also had a moderate potency in inhibiting the oxidation of CLZ by CYP3A4. These results suggest that PGD suppression of CLZ metabolism appears to be at least partly derived from the inhibition of related CYP enzymes, in particular CYP1A2 and CYP3A4.
In addition to CYPs, HLM also express abundant FMOs (Krueger et al., 2005 the oxygenation of CLZ (Fang et al., 1998; Fang, 2000; Tugnait et al., 1997; . In the present study, we revealed that, under physiological conditions, the production of CLZ metabolites, CLZ-N-oxide and norCLZ, was not different between partial and full activation of FMOs in the presence and absence of the coenzyme NADPH, respectively. In contrast, the amount of BZD-N-oxide, an index of FMO reactions and produced in the presence of NADPH, was almost doubled compared to that produced in the absence of NADPH. It is likely then that the human hepatic FMO-mediated metabolic pathway plays a relatively minor role in the biotransformation of CLZ. Similar results were also observed in a previous study , demonstrating that N-oxide formation of CLZ in HLM was not affected when FMO activity was selectively inhibited. On the other hand, FMO3 is the prominent functional form in the human hepatic FMO system (Tugnait et al., 1997) .
We thus evaluated the potential of PGD in mediating FMO3 activity using recombinantly expressed FMO3. The current study showed that PGD in effective pharmacological concentration (2.5 and 5 mg/ml) presented a slight effect (<12%) in inhibiting FMO3 from catalyzing the N-oxide formation of CLZ. Even at 10-25 mg/ml, 4-to 10-fold higher than the reference concentration (2.5 mg/ml), the inhibitory magnitude still could not reach the IC 50 level (44.3 mg/ml) at which 50% of the production of CLZ-N-oxide should be suppressed. Taken bioactive constituents of PGD may play a relatively minor role in the inhibitory effects of PGD on human liver CYP enzymes. Given that the anti-hyperPRL effects of PGD are closely associated with the constituents tested (Wang et al., 2012a; Yuan et al., 2008) , it is unlikely that the anti-hyperPRL effects of PGD observed previously (Wang et al., 2012a; Yuan et al., 2008) Here, we provide pharmacokinetic evidence supporting such synergistic herb-herb interaction. In further support of our hypothesis, it has been found that the interaction potential on CYP3A4 of liquorice extract was greater than for the pure compound (Tsukamoto et al., 2005) . Combinations of peony and liquorice in different ratios resulted in significant differences in the bioavailability of the major bioactive constituents . There were also marked differences in gastrointestinal In summary, this study suggests that PGD has the capacity to suppress CLZ metabolism in the human liver microsomal system. This suppression is mainly associated with the inhibition of related CYP activity, in particular CYP1A2 and CYP3A4 but not FMOs. The known pharmacologically active constituents contained in PGD may play relatively minor role in kinetic interactions of PGD with CLZ.
Further, it suggests that further investigation into herb-drug interactions may be of interest. This article has not been copyedited and formatted. The final version may differ from this version. (CLZ-N-oxide), were measured. IC 50 of PGD in inhibiting the production of CLZ-N-oxide and norCLZ was 2.41 mg/ml and 2.00 mg/ml, respectively.
Experiments were conducted in triplicate (n = 3). Tables   TABLE 1  Kinetic effects 21.9 ± 2.6 6.3 ± 1.2* 15.6 ± 0.3 20.5 ± 3.5 8.1 ± 1.6* a The data are expressed as mean ± SEM (n = 3) and analyzed using one-way ANOVA, followed by Dunnett's methods for multiple pair comparisons. * P < 0.05 vs. control.
b PGD, Peony-Glycyrrhiza Decoction; PR, Paeonia radix (peony) preparation; GR, Glycyrrhiza radix (liquorice) preparation; CLZ, clozapine; norCLZ, N-demethyl-clozapine; CLZ-N-oxide, clozapine-N-oxide. This article has not been copyedited and formatted. The final version may differ from this version. a The data are expressed as mean ± SEM (n = 3) and analyzed using two-sided Student t-test. * P < 0.05 vs. NADPH (+) with the same substrate. BZD, benzydamine; CLZ, clozapine; NADPH, nicotinamide adenine dinucleotide phosphate.
